Gabby Migliara is a manager of public affairs at PhRMA focusing on the cost and value of medicines. She previously worked with the U.S. Census Bureau on marketing and communications for the 2020 Census campaign. Outside the office, Gabby enjoys trying new restaurants, hanging with her cat and exploring DC neighborhoods.
Recent Posts
Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds
By Gabby Migliara | November 19, 2020
A new analysis by IQVIA looked at three cost-sharing assistance programs and found that from 2018 to 2020, 25% to 36% of patients discontinued treatment when they faced an unexpectedly high...
Read More
Study: Hospital and outpatient care are biggest drivers of health care spending differences between the United States and other countries
By Gabby Migliara | October 22, 2020
A number of past analyses have shown that hospitals drive U.S. health care spending. In fact, data released last year showed that the United States spends three times more per person on hospital...
Read More
Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
By Gabby Migliara | October 21, 2020
Medicines are responsible for more than a third of the improvement in life expectancy from 1990 to 2015, according to a recent study published in Health Affairs. This underscores the crucial role...
Read More
Survey found insurance premiums grew faster than inflation in 2020
By Gabby Migliara | October 20, 2020
According to Kaiser Family Foundation’s recent survey on employer health benefits, premiums for people with employer-sponsored health insurance increased by 4% last year, faster than both the rate...
Read More
Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually
By Gabby Migliara | August 19, 2020
A recent analysis by IQVIA shows that chronically ill patients who used manufacturer cost-sharing assistance in 2019 saved hundreds to thousands of dollars on their out-of-pocket costs. IQVIA...
Read More
Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas
By Gabby Migliara | August 12, 2020
According to a recent IQVIA analysis, commercial health plans have increased patients’ average out-of-pocket costs for brand medicines by over 50% in some therapeutic areas since 2015. Notably, of...
Read More
Commercial health plans’ transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs for brand medicines
By Gabby Migliara | August 6, 2020
A decade ago, most patients paid only copays for brand medicines. But in recent years, use of deductibles and coinsurance in commercial health plans has skyrocketed. According to a recent IQVIA...
Read More
New data show commercially insured patients face increasingly high cost sharing for brand medicines
By Gabby Migliara | July 30, 2020
New data show deductibles and coinsurance result in high out-of-pocket spending for commercially insured patients taking brand medicines. IQVIA analyzed trends in cost sharing across seven therapy...
Read More
Payers subject 80% of new RA and MS patients to utilization management restrictions
By Gabby Migliara | July 22, 2020
A new analysis from IQVIA shows that in 2018, 80% of commercially insured patients attempting to fill a new prescription for a rheumatoid arthritis (RA) or multiple sclerosis (MS) medicine...
Read More
Study finds the pharmaceutical industry retains a smaller share of revenue than research-intensive industries
By Gabby Migliara | July 14, 2020
A new study from Oxford Economics found the pharmaceutical industry retains a considerably smaller share of total spending on its products than other research-intensive industries, despite...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
